Treatment for Adult HIV Infection
Top Cited Papers
- 14 July 2004
- journal article
- guideline
- Published by American Medical Association (AMA) in JAMA
- Vol. 292 (2) , 251-265
- https://doi.org/10.1001/jama.292.2.251
Abstract
ContextSubstantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection.ObjectiveTo update recommendations for physicians who provide HIV care regarding when to start antiretroviral therapy, what drugs to start with, when to change drug regimens, and what drug regimens to switch to after therapy fails.Data SourcesEvidence was identified and reviewed by a 16-member noncompensated panel of physicians with expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care. The panel was designed to have broad US and international representation for areas with adequate access to antiretroviral management.Study SelectionEvidence considered included published basic science, clinical research, and epidemiological data (identified by experts in the field or extracted through MEDLINE searches using terms relevant to antiretroviral therapy) and abstracts from HIV-oriented scientific conferences between July 2002 and May 2004.Data ExtractionData were reviewed to identify any information that might change previous guidelines. Based on panel discussion, guidelines were drafted by a writing committee and discussed by the panel until consensus was reached.Data SynthesisFour antiretroviral drugs recently have been made available and have broadened the options for initial and subsequent regimens. New data allow more definitive recommendations for specific drugs or regimens to include or avoid, particularly with regard to initial therapy. Recommendations are rated according to 7 evidence categories, ranging from I (data from prospective randomized clinical trials) to VII (expert opinion of the panel).ConclusionFurther insights into the roles of drug toxic effects, drug resistance, and pharmacological interactions have resulted in additional guidance for strategic approaches to antiretroviral management.Keywords
This publication has 35 references indexed in Scilit:
- The Prognostic Importance of Changes in CD4^+Cell Count and HIV-1 RNA Level in Women after Initiating Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2004
- Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionNew England Journal of Medicine, 2003
- Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 InfectionNew England Journal of Medicine, 2003
- Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Patients Who Achieve Durable Virologic Suppression: Longer Follow‐Up of an Observational Cohort StudyThe Journal of Infectious Diseases, 2003
- Higher Baseline Levels of Plasma Human Immunodeficiency Virus Type 1 RNA Are Associated with Increased Mortality after Initiation of Triple‐Drug Antiretroviral TherapyThe Journal of Infectious Diseases, 2003
- Duration of Highly Active Antiretroviral Therapy RegimensClinical Infectious Diseases, 2003
- Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesThe Lancet, 2003
- Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort studyThe Lancet, 2002
- Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in BrazilAIDS, 2001